The examples and perspective in this section deal primarily with the United States and do not represent a worldwide view of the subject. (June 2019) (Learn how and when to remove this template message)
Daflon is not an FDA-approved medication, meaning that it cannot be advertised for treatment of diseases. However, experimental trials reported it could benefit some people. It is believed daflon is a venotonic (it increases venous tone) and a vasculoprotector (it increases resistance in small blood vessels). It is used experimentally for treating Chronic venous insufficiency and for treating Hemorrhoidal diseases. In an experiment, daflon was found beneficial in the reduction of symptoms after operation for hemorrhoidal disease.
Even though Daflon is not a prescription medication in the US, it is in other countries like France. Also diosmiplex, which is also a MPFF (micronized purified flavonoid fraction), with similar venous insufficiency indication, is a prescription medication in the US.
For venous insufficiency, the dosage is 2 tablets daily. For acute hemorrhoidal attack, the dosage is 6 tablets daily for 4 days, followed by 4 tablets daily over the next 3 days.
Possible side effects include routine gastric disorders and neurovegetative disorders.
- "Offocial Monograph. Daflon 500: Summary of Product Characteristics" (PDF). www.servier.com.ve. Archived (PDF) from the original on 2016-12-28. Retrieved 2018-12-09.
- Lyseng-Williamson KA, Perry CM (2003). "Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids". Drugs. 63 (1): 71–100. doi:10.2165/00003495-200363010-00005. PMID 12487623.
- "Daflon 500 mg in the management of acute and recurrent hemorrhoidal disease" (PDF). Phlebolymphology: 281–282. Retrieved 10 April 2015.
- Astashov, Vladimir L.; Timchenko, Dmitry A. (2014-03-18). "Benefits of micronized purified flavonoid fraction in the reduction of symptoms after operation for hemorrhoidal disease". Phlenolymphology.org. Phlebolymphology. Retrieved 10 April 2015.
- "DAFLON - EurekaSanté par VIDAL". EurekaSanté (in French). Retrieved 2018-02-17.
- "Notice patient - DAFLON 500 mg, comprimé pelliculé - Base de données publique des médicaments". base-donnees-publique.medicaments.gouv.fr (in French). Retrieved 2018-02-17.
- Bush, Ronald; Comerota, Anthony; Meissner, Mark; Raffetto, Joseph D.; Hahn, Steven R.; Freeman, Katherine (April 2017). "Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF)". Phlebology. 32 (1_suppl): 3–19. doi:10.1177/0268355517692221. ISSN 1758-1125. PMID 28211296.
- de Souza, Maria das Graças C.; Cyrino, Fatima Z. G. A.; Mayall, Monica R.; Virgini-Magalhães, Carlos E.; Sicuro, Fernando L.; de Carvalho, Jorge José; Verbeuren, Tony J.; Bouskela, Eliete (February 2016). "Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon® 500 mg) on microvascular damage elicited by sclerotherapy". Phlebology. 31 (1): 50–56. doi:10.1177/0268355514564414. ISSN 1758-1125. PMID 25514922.
- Martinez-Zapata, Maria José; Vernooij, Robin W. M.; Uriona Tuma, Sonia Maria; Stein, Airton T.; Moreno, Rosa M.; Vargas, Emilio; Capellà, Dolors; Bonfill Cosp, Xavier (2016-04-06). "Phlebotonics for venous insufficiency". The Cochrane Database of Systematic Reviews. 4: CD003229. doi:10.1002/14651858.CD003229.pub3. ISSN 1469-493X. PMID 27048768.